You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥-B(06996.HK):超額認購264倍上限定價18.08港元,明日正式登陸港交所
格隆匯 11-19 09:31

格隆匯 11 月 19日丨專注於創新抗腫瘤藥物的生物製藥公司德琪醫藥-B(06996.HK)發佈公告,公司全球發售約1.54億股股份,其中香港發售股份7707.7萬股,國際發售股份7707.65股,另有15%超額配股權;發售價釐定為每股發售股份18.08港元,每手買賣單位500股,一手入場費9131.09港元;高盛及摩根大通為聯席保薦人,預期股份將於2020年11月20日於聯交所主板掛牌上市。

香港公開發售項下初步發售的香港發售股份獲大幅超額認購。合共接獲229,916份有效申請,認購合共約40.81億股,相當於香港公開發售項下初步可供認購股份總數約264.76倍。國際發售項下初步提呈發售的發售股份已獲超額認購,相當於國際發售項下初步可供認購發售股份總數的約13.5倍。

德琪醫藥是一家領先的專注於創新抗腫瘤藥物的生物製藥公司。目前,公司共計擁有12種用於治療腫瘤的在研產品,其中包括2種晚期臨牀資產、4種早期臨牀資產和6種臨牀前資產。截止公司招股書披露,目前公司有9項正在進行臨牀試驗,5項計劃啟動臨牀試驗,並在亞太多地區收到9項IND批准。

據招股書披露,德琪醫藥本次IPO引入10名基石投資者,包括富達、GIC(新加坡政府投資公司)、貝萊德、博裕、Cormorant、高瓴、紅杉資本、晨嶺資本、Laurion Capital及Octagon Investments等醫療健康行業知名機構投資者,合共投資金額1.79億美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account